Arvinas’ newly elected Chair of the Board of Director said that the company chose Randy as CEO “after a comprehensive search.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...

As of November 27, 2023, the average one-year price target for Arvinas is 55.14. The forecasts range from a low of 20.20 to a high of $99.75. The average price target represents an increase of 137.98% ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

ARVN stock is receiving a lot of attention. And for good reason. Arvinas (Nasdaq: ARVN) is heading in the right direction due to the results of recent clinical trials. The Connecticut-based company ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...

AR VN RVN stock from one of the Wall Street analysts, citing development challenges for its cancer treatment - ARV-471. Larger pharmaceutical companies, Sanofi and Roche, have seen failures in their ...